Pfizer delays patent cliff for blockbuster Vyndamax
Pfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three best-selling medicines and vaccines. Vyndamax is approved for a heart ...
April 28, 2026 01:36 PM EDTUpdated 03:22 PM PharmaMarketingLaw Pfizer delays patent cliff for blockbuster heart drug Nicole DeFeudis Senior Reporter Pfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that